Introduction

The Women’s Health sector is experiencing a surge in investment and innovation, signalling a major shift in the MedTech industry. Historically, therapeutic areas such as Cardiovascular saw surges in investment, but in 2024, Women's Health has emerged as a key focus. This presents a wealth of opportunities for MedTech service providers looking to support innovation in this growing field.

Companies Leading Innovation in Women’s Health

One of the most compelling indicators of the rise of Women’s Health is the substantial increase in funding it has experienced. In the past 20 years, 2024 saw the largest amount of investment into Women's Health. This surge signals a growing recognition of the importance of addressing Women’s Health issues, and this funding is poised to fuel innovation and development in this area. Several Women’s Health focused companies have made significant advancements in this area, securing investments to drive their innovations:

• Willow Innovations – Developed the Willow® Wearable Breast Pump, offering hands-free, portable convenience for breastfeeding mothers.
• Establishment Labs – Specializes in advanced breast implant technologies, enhancing both aesthetics and patient safety.
  TMRW Life Sciences – Created the first FDA-cleared automated platform for frozen egg and embryo storage, modernizing IVF labs.
• Materna Medical – Focuses on pelvic health solutions, including vaginal dilators and devices designed to reduce pelvic floor injuries during childbirth.
• Bloom Technologies – Offers a connected care platform for maternal health, providing remote monitoring and data analytics to optimize care for high-risk pregnancies.

A Landscape Dominated by Early-Stage Companies

The Women’s Health sector is still largely composed of early-stage companies. Approximately 30% of companies in this space have between 1 and 10 employees, while another 35% have 11 to 50 employees, indicating that a significant portion of businesses in this industry are still in their growth phase.

This trend is further reflected in the founding dates of these companies. Nearly 40% of Women’s Health companies have been established in the last decade, highlighting how recent innovation has fuelled growth in this sector. Because many of these companies are in their early stages, they are often pre-revenue or just beginning to generate revenue, making them highly reliant on external investment to scale their operations.

Larger companies in this space, by contrast, tend to have more established revenue streams that sustain their business operations without requiring as much external funding. The disparity in size and funding also indicates that while Women’s Health is growing rapidly, many companies are still in the process of scaling their technologies and gaining market traction.

Investment Driving Clinical Advancements

The surge in funding is expected to drive increased clinical activity in the coming year. In MedTech, clinical trials often follow investment by 6 to 12 months, meaning that the recent rise in funding in Women’s Health will likely lead to a wave of new clinical trials.

Currently, about 35% of companies working in Women’s Health are in the pre-clinical stage, reinforcing the sector’s early-stage nature. As these companies move towards commercialization, they will require support in regulatory compliance, clinical trials, and manufacturing.

Opportunities for MedTech Service Providers

The rise of Women’s Health presents significant opportunities for service providers that can tailor their offerings to meet the sector’s evolving needs. As these companies progress, demand for support in clinical trials, regulatory compliance, and advanced manufacturing will continue to grow, creating opportunities for service providers that can deliver these essential capabilities. 

With a large portion of Women’s Health companies still in the early stages, the need for scalable, cost-effective solutions is expected to rise. Companies specializing in these cost-effective services—such as regulatory consulting, preclinical testing, quality assurance, and prototype development—will have a vast market in the coming years, given the high number of small companies in this space.

By closely tracking funding trends, company maturity, and clinical trial activity, MedTech stakeholders can stay ahead of the curve and capitalize on the rapid expansion of Women’s Health. With innovation and patient-centric solutions at the forefront, Women’s Health is poised to become a transformative force in the MedTech industry in the years to come. 

How Zapyrus Can Help Service Providers Seize Opportunities in Women’s Health

As Women’s Health investment rises, MedTech service providers need to be able to identify opportunities and engage the right companies. Zapyrus is your partner in growth, helping MedTech service providers grow their client base, improve operational efficiency, and drive results.

With AI-driven insights and automation, Zapyrus empowers service providers to:

1. Identify high-potential companies and track industry trends
2. Streamline outreach to key decision-makers with hyper-personalized engagement
3. Accelerate deal closures and strengthen client relationships

Stay ahead in the evolving MedTech landscape, let Zapyrus help you unlock new opportunities and scale smarter.